BioSpace News Archive

ViewRay, Inc., maker of the MRIdian, which combines MRI and external-beam radiation therapy to simultaneously image and treat cancer patients, announced the completion of its previously announced underwritten public offering of 11,856,500 shares of common stock at a price to the public of $4.85 per share, for gross proceeds of approximately $57.5 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by ViewRay.

Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, today announced that the company will participate in the 39th Annual J.P. Morgan Healthcare Conference, a fully virtual management access conference. President and Chief Executive Officer, Mark Foley, is scheduled to present on Thursday, January 14, at 12:40 p.m. PT / 3:40 p.m. ET. Inter

Emerging psychedelic drug development company Diamond Therapeutics has received new investment from the Ontario Brain Institute, a not-for-profit organization that accelerates discovery and innovation, benefiting both patients and the economy.

Erasca, a company whose mission is to erase cancer, announced that Wei Lin, M.D., has joined as chief medical officer

Standigm Inc. (“Standigm”), an artificial intelligence (AI)-based drug discovery company and SK Chemicals Co., Ltd. (“SK Chemicals”), a life science and green chemicals company, announce today that they have successfully found a new rheumatoid arthritis indication for an FDA-approved drug and have filed a patent.

Focus on Therapeutic Outcomes (FOTO), a Net Health Company, has been approved for the 13th consecutive year by the Centers for Medicare & Medicaid Services (CMS) as a data registry for CMS payment programs, and for the third consecutive year as a Qualified Clinical Data Registry (QCDR) for 2021.

Cyteir Therapeutics, a leader in the discovery and development of next-generation synthetic lethal therapies to treat cancer, today announced that Markus Renschler , M.D., Cyteir’s president and chief executive officer, will present a scientific and business update at the 39th Annual J.P. Morgan Healthcare Conference on Monday,

Through this license agreement, SIRION Biotech GmbH (“SIRION”) granted Cellectis non-exclusive right under its proprietary lentiviral transduction enhancer LentiBOOST™. This product complements Cellectis’ portfolio of technologies involved in manufacturing allogeneic CAR T-cells. SIRION is entitled to undisclosed upfront and milestone payments and is eligible to receive royalties on future product net sa

- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage rare liver disease company developing novel bile acid modulators, today announced that it will host a virtual Commercial Day for investors on February 11 from 11:30-1:00pm EST. Presentations will include an overview of the long-term corporate strategy, the global market opportunity in rare pediatric and adult liver disease, and the global commercialization strategy and launch readiness plans for o

TheraLight, LLC, a privately held U.S.-based medical device company specializing in photomedicine, announced the relocation and expansion of its corporate headquarters to a new office and warehouse in Lindon, Utah to advance the operations and growth of the company.